CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER bulk active fine chemical sources

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
ASINEX	⤷ Get Started Free	BAS 06989041	⤷ Get Started Free
Aronis	⤷ Get Started Free	ARONIS020379	⤷ Get Started Free
NovoSeek	⤷ Get Started Free	2764	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 3, 2025

Introduction

The procurement of high-quality Active Pharmaceutical Ingredients (APIs) is a critical determinant of pharmaceutical product efficacy, safety, and regulatory compliance. Ciprofloxacin, a broad-spectrum fluoroquinolone antibiotic, remains a cornerstone in treating various bacterial infections. When formulated as CIPRO in Dextrose 5% in plastic containers, the API’s source influences product stability, bioavailability, and regulatory approval across markets. This report examines global API supplies, key manufacturers, sourcing considerations, and industry trends pertinent to CIPRO API used specifically for injectable formulations.

Overview of Ciprofloxacin API

Ciprofloxacin API (Chemical Abstracts Service No. 85721-33-1) is synthesized predominantly via chemical processes involving complex halogenation, fluorination, and purification steps. Its pharmaceutical grade is under stringent quality standards, including Good Manufacturing Practices (GMP), to meet the demands of sterile injectable formulations like CIPRO in Dextrose 5%.

Given the sensitive nature of injectable APIs, sourcing from reputable manufacturers with validated processes is essential to ensure API purity (>99%), endotoxin levels, residual solvents, and compliance with pharmacopeial standards [1].

Major Global API Manufacturers for Ciprofloxacin

Several key global players dominate the API manufacturing landscape for ciprofloxacin, with capabilities to supply bulk quantities suitable for manufacturing CIPRO in Dextrose 5%:

1. Teva Pharmaceuticals

Overview: An Israeli global pharmaceutical company with extensive API manufacturing facilities.
Capabilities: Produces high-quality ciprofloxacin API compliant with USP, EP, and JP pharmacopoeias.
Strengths: Proven track record in sterile APIs, robust GMP compliance, and global distribution networks.

2. Sandoz (Novartis)

Overview: A division of Novartis known for specialty generics and APIs.
Capabilities: Supplies ciprofloxacin API manufacturing at scale, with focus on sterile injectable grade APIs.
Strengths: Strong regulatory support and global manufacturing footprint.

3. Zhejiang Hisun Pharmaceutical Co., Ltd.

Overview: Chinese manufacturer with significant API production capacity.
Capabilities: Produces ciprofloxacin API meeting international standards, with verified GMP certification.
Strengths: Competitive pricing, expanding global footprint, and reliable supply.

4. Changzhou Siyao Pharmaceutical Co., Ltd.

Overview: Chinese API producer specializing in antibiotics.
Capabilities: Offers ciprofloxacin bulk API for sterile and non-sterile formulations.
Strengths: Cost-effective, with quality compliance aligned to global standards.

5. Lupin Limited

Overview: Indian pharmaceutical manufacturer with substantial API production.
Capabilities: Supplies ciprofloxacin API suitable for sterile and injectable formulations.
Strengths: Competitive pricing, reliable quality, and extensive global distribution.

Sourcing Considerations for CIPRO API

Quality and Regulatory Compliance

Certifications such as cGMP, ISO standards, and pharmacopoeial compliance (USP, EP, JP) are non-negotiable. Suppliers should provide batch-specific Certificates of Analysis (CoA), stability data, and endotoxin profiles, considering the injectable nature of the final product.

Supply Stability and Capacity

Manufacturers with proven supply chain resilience and sufficient capacity mitigate risks of shortages, especially for sterile APIs like ciprofloxacin used in CIPRO 5% in Dextrose formulations. Strategic partnerships with established API suppliers ensure continuous production without compromising quality.

Pricing and Lead Times

While cost competitiveness is vital, balancing price with quality assurance is crucial. Lead times vary based on the manufacturing scale, regulatory clearance, and logistics; early engagement with suppliers mitigates delays.

Geopolitical and Regulatory Environment

Selecting sources compliant with local and international regulators (FDA, EMA, PMDA) prevents delays in registration and market approval. Global API suppliers often hold multiple regulatory approvals, easing compliance burdens.

Emerging Trends and Industry Insights

API Synthesis Innovations: Advances in green chemistry and process optimization enhance yield, purity, and environmental sustainability.
Global Supply Chain Diversification: The COVID-19 pandemic underscored the importance of diversified sourcing to prevent supply disruptions.
Regulatory Harmonization: Increased standardization across regions simplifies supplier qualification procedures.
Vertical Integration: Major pharmaceutical companies increasingly develop in-house API production to ensure quality control and supply security.

Conclusion

The reliable sourcing of ciprofloxacin API for use in sterile formulations like CIPRO in Dextrose 5% in plastic containers necessitates engagement with reputable, GMP-compliant manufacturers. Leading global suppliers such as Teva, Sandoz, and Indian and Chinese API producers provide scalable, compliant, and high-quality APIs—critical for maintaining product integrity. Due diligence encompassing quality certifications, supply capacity, and regulatory status ensures seamless procurement, minimizing risk and optimizing manufacturing efficiency.

Key Takeaways

The choice of API supplier directly impacts the quality and regulatory approval of CIPRO in Dextrose 5%.
Reputable manufacturers with proven GMP compliance and extensive regulatory approvals are preferred for sterile API sourcing.
Diversification of sources and early supplier engagement mitigate supply chain risks.
API innovations and industry trends favor environmentally friendly processes and supply chain resilience.
Strategic sourcing aligned with regulatory standards accelerates time-to-market and ensures product quality.

FAQs

1. What are the primary factors to consider when sourcing ciprofloxacin API for injectable formulations?
Quality compliance (GMP standards, pharmacopoeial certifications), supply reliability, regulatory approvals, and cost-effectiveness are paramount.

2. Which regions dominate ciprofloxacin API production?
China and India are leading producers due to cost advantages, while countries like Israel and Switzerland host some high-quality, regulated API manufacturers.

3. How does API quality affect the stability of CIPRO in Dextrose 5% formulations?
High-purity APIs with low residual solvents and endotoxins ensure stability, reduce contamination risks, and maintain efficacy during storage.

4. Are there alternatives to external API sourcing for ciprofloxacin?
Yes, some pharmaceutical companies develop in-house API production; however, outsourcing from established API manufacturers remains common.

5. What advances have been made to improve ciprofloxacin API manufacturing?
Process optimization, green chemistry initiatives, and stricter quality controls have enhanced API purity, yield, and environmental sustainability.

References

[1] U.S. Pharmacopeia (USP), "General Chapter <741> – Tests for Uniformity," USP 43-NF 38, 2020.

Bulk Pharmaceutical API Sources for CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER